In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex landscape of challenges and opportunities in recent months. According to ...

The drug has been approved under the brand name Ordspono. Investors will also look for key pipeline updates from Regeneron apart from the top and bottom-line numbers. REGN filed an application ...

Mucinex knocked Vicks off the top spot for monthly TV ad impressions as pharma brands generated significant coverage from ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

The fourth-quarter earnings season for the biotech sector is in full swing this week. A few bigwigs have already reported ...

D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

Spotify (NYSE: SPOT) stock surged 8.3% after the music streaming company reported fourth-quarter 2024 results that exceeded ...

Health Canada has given the drug a green light – under the Sohonos brand – to treat fibrodysplasia ... over its main rival in the FOP space, Regeneron, which has had it own problems bringing ...